

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

10/574416

In re Application of
Grueneberg et al.

Examiner: **Unknown**

APR 20 2006
31 MAR 2006

Art Unit: **Unknown**

Application No.: **To Be Assigned**

Filed: **Herewith**

Title: **Retroviral Vectors For Delivery of
Interfering RNA**

I hereby certify that this correspondence is being
deposited with the United States Postal Service as
Express Mail in an envelope addressed to
Commissioner for Patents, P.O. Box 1450, Alexandria,
VA 22313-1450, on

March 31, 2006
Date of Deposit

Debra Cropper
Signature

EL964833655US
Express Mail No.

**STATEMENT REGARDING CONTENT OF PAPER AND COMPUTER READABLE
COPIES PURSUANT TO 37 C.F.R. 1.821 (f)**

Mail Stop
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

The undersigned states that the content of the nucleotide and/or amino acid sequences set forth in the "Sequence Listing" part of the enclosed patent application required by 37 C.F.R. 1.821 (c) and the computer readable copies required by 37 C.F.R. 1.821 (e) submitted herewith are the same.

Respectfully submitted,

Karen Krupen
Karen I. Krupen, Reg. No. 34,647
Attorney for Applicant

sanofi-aventis U.S. LLC
U.S. Patent Operations
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Telephone (908) 231-4658
Telefax (908) 231-2626

sanofi-aventis Docket No. USAV2002/0187 US PCT